Merck, Eisai Get Europe OK for Lenvima/Keytruda Combination in Two Cancers
29 November 2021 - 11:28PM
Dow Jones News
By Colin Kellaher
Merck & Co. and Eisai Co. on Monday said the European
Commission has approved the combination of the combination of
Eisai's Lenvima and Merck's Keytruda in a pair of indications.
Merck, based in Kenilworth, N.J., and Tokyo-based Eisai said the
approvals include the combination for the first-line treatment of
adults with advanced renal cell carcinoma, the most common type of
kidney cancer.
The companies said the combination is also now approved for
adults with advanced or recurrent endometrial cancer who have
disease progression on or following prior treatment with a
platinum-containing therapy in any setting and who aren't
candidates for curative surgery or radiation.
Eisai and Merck in March 2018 formed a collaboration to jointly
develop, manufacture and commercialize Lenvima as monotherapy and
in combination with Merck's blockbuster cancer drug Keytruda.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 29, 2021 07:13 ET (12:13 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Eisai (PK) (USOTC:ESALY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eisai (PK) (USOTC:ESALY)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Eisai Company Ltd (PK) (OTCMarkets): 0 recent articles
More Eisai Company Ltd (PK) News Articles